Chronic Hepatitis B – Market Access and Reimbursement Insights Report – 2025

Chronic Hepatitis B Market Access and Reimbursement Insights

Thelansis’s “Chronic Hepatitis B Market Access and Reimbursement Insights Report – 2025″ provides comprehensive payer insights on the current and evolving market access and reimbursement environments for branded and emerging drugs in the indication. Our team understands the criticality of payer research and insights generation, as well as their importance during drug development, pre-market launch strategy, and post-marketing activities.

Chronic Hepatitis B Overview

Chronic Hepatitis B (CHB) infection is characterized by the presence of Hepatitis B surface antigen (HBsAg) in the serum for at least six months. Whereas HBsAg indicates the presence of hepatitis B viral infection, the markers HBeAg and HBV DNA, as determined by polymerase chain reaction (PCR) assays, are indicators of viral replication and infectivity. Severe complications associated with chronic infection encompass cirrhosis, liver failure, hepatocellular carcinoma, and mortality. In a minority of cases, HBV DNA can be detected in the serum without concurrent HBeAg presence. This phenomenon is attributed to the “pre-core” mutant, which impedes the production and release of the “e” antigen, despite ongoing HBV DNA replication and is associated with progressive liver disease. Following an acute HBV infection, the risk of developing chronic hepatitis B varies with age; less than 5% of adults develop chronic illnesses, whereas 90% of infants do so. Significant long-term complications like chronic hepatitis, cirrhosis, or hepatocellular carcinoma (HCC) can result from HBV transmission in children aged five and under.

Geography coverage:

G8 (United States, EU5 [France, Germany, Italy, Spain, U.K.], Japan, and China)

Insights driven by surveys* and interviews with payers (e.g., pharmacy directors / medical directors from managed care organizations with Medicare and/or Commercial plans in the United States). If required, primary market research with physicians is also done to understand the impact of reimbursement environment on treatment decisions for current and emerging brands.

*Survey and interview discussion guide are customized based on client requirements

Deliverables format:

• PowerPoint presentation

*As per Thelansis’s policy, we ensure that we include all the recent updates before releasing the report content and market model.

Key business questions answered:

• Market access and reimbursement for current therapies
• Coverage on plans
• Market access restrictions
• Rebates and contracting
• Factors influencing formulary access
• HEOR requirements and influence, etc.
• Expected market access and reimbursement for key emerging therapies
• Level of awareness
• Anticipated coverage on plans
• Factors that would improve market access
• Pricing, etc.
• Impact on brand use
• Key factors driving and limiting brand use
• Best and worst performers on market access, etc.
• Evolving environment
• Payer expectations from emerging therapies
• New policies and their expected impact, etc.
• Advise to drug manufacturers and developers

Read more: Chronic Hepatitis B – Market Access and Reimbursement Insights Report – 2025